Smoking Cessation and Nicotine De-addiction Market – By Product Type, By Route of Administration, By Distribution Channel - Global Forecast 2025 – 2034

Smoking Cessation and Nicotine De-addiction Market Size

The global smoking cessation and nicotine de-addiction market size was valued at around USD 25.5 billion in 2024 and is estimated to grow at 12% CAGR from 2025 to 2034. Smoking cessation is the process in which an individual discontinues tobacco use through nicotine replacement therapies and medical treatments alongside behavioral change.
 

Nicotine de-addiction is a broad concept that includes the process of overcoming a psychological and physiological dependency on nicotine typically caused by cigarette smoking or vaping. It usually includes counseling, medical care, and other forms of therapeutic measures and helps to recover smokers, prevent relapse, and handle withdrawal effects.
 

Rising awareness towards the negative effects of smoking is accelerating the market of smoking cessation and nicotine de-addiction solutions. Lung cancer cases are expected to rise due to rise in smoking. For example, according to the Centers for Disease Control and Prevention (CDC), cigarette smoking is estimated to cause 90% of all lung cancers. Moreover, WHO has estimated around 2.5 million new lung cancer cases in 2024 which would make it the leading cancer type accounting for 12.4% of all reported cancers. This condition has substantial impacts economically and socially, highlighting the growing need for anti-smoking interventions.
 

Additionally, government programs and initiatives such as plain packaging laws, public place smoking bans, and higher tobacco taxes are promoting smoking cessation among the public. For instance, the WHO’s Framework Convention on Tobacco Control (FCTC) policy aims to reduce smoking through awareness campaigns and the provision of medical helps. In addition, development and approval of novel nicotine replacement products and therapies like gums, inhalers, and E-cigarettes is increasing the success rates of smoking cessation. For example, in January 2025, the U.S. FDA declared the marketing approval of 20 new ZYN nicotine pouch products under the PMTA pathway.
 

Smoking Cessation and Nicotine De-addiction Market Trends

• Support for remote virtual support groups, online counseling services, online mHealth consultations, and prescription services for NRT medications are increasing, and impacting the market growth. These trends are positively influencing smoking cessation rates and the adoption of NRT products.
   
• Investments in research and development by the market players in nicotine pouches, E-cigarettes, NRT nicotine inhalers, and nicotine patches and gums is also increasing as they are focusing towards increasing their penetration in the markets with Never Been Seen Before (NBS) products. For example, in April 2024, Kenvue announced that its nicotine patch and gum were the first NRT products to receive WHO-prequalification. Such initiatives from government bodies and companies are increasing cessation of smoking which is contributing to market growth.
   

Smoking Cessation and Nicotine De-addiction Market Analysis

Based on product type, the market is segmented into nicotine replacement therapy, drug therapy, and E-cigarettes and vapes. The global market for smoking cessation and nicotine de-addiction was valued at USD 23 billion in 2023. The E-cigarettes and vapes segment dominated the market with the largest revenue share of 49.8% in 2024.
 

• The increasing prevalence of lung cancer caused by tobacco consumption is driving the demand for smoking cessation and nicotine replacement therapy products. For instance, according to the American Cancer Society, approximately 81% of the total lung cancer deaths in 2024 are expected to be directly caused by cigarette smoking.
   
• The growing awareness among smokers regarding the harmful consequences of cigarette smoking is promoting the transition towards vapes and E-cigarettes as a less harmful alternative as compared to traditional combustible tobacco, particularly among younger demographics in Europe and North America.
   
• Additionally, governments across different countries are imposing much stricter tariff rates, restrictions, and regulations, along with increased taxation on tobacco products. Such initiatives are driving the use of E-cigarettes and vapes as alternatives to the habitual smokers around the globe which is boosting the segment’s growth.
   

Based on route of administration, the smoking cessation and nicotine de-addiction market is segmented into oral, transdermal, nasal, inhalation, and sublingual. The inhalation segment dominated the market with the largest revenue share of 50.1% in 2024.
 

• The increasing adoption of nicotine inhalers, vapes, and E-cigarettes is promoting the growth of the inhalation administration segment.
   
• Additionally, the introduction and adoption of novel nicotine inhalers as a major nicotine replacement therapy products for smoking cessation is driving the segment growth. For instance, in June 2024, the UK Medicines and Healthcare products Regulatory Agency (MHRA) announced the approval of Ayrton Saunders Limited’s patented nicotine inhaler system.
   

Based on distribution channel, the smoking cessation and nicotine de-addiction market is segmented into hospital pharmacies, retail pharmacies, and E-commerce. The retail pharmacies segment dominated the market with the largest revenue of 11.5 billion in 2024 and is expected to reach USD 35 billion by 2034.
 

• Retail pharmacies are the most accessible and convenient channels to purchase nicotine replacement therapies such as inhalers, lozenges, patches, and gums. The high consumer preference towards OTC NRT products rather than prescription products promotes the adoption of retail stores, driving the segment growth.
   
• Additionally, the increasing expansion of major pharmacy retail chains such as Boots, Walgreens, and CVS has increased the accessibility and availability of a wide range of smoking cessation and NRT products.
   

The revenue of U.S. smoking cessation and nicotine de-addiction market in North America is expected to increase considerably from USD 8.9 billion in 2024 to USD 26.7 billion by 2034.
 

• The increasing prevalence of lung cancer in the U.S., especially among young adults due to cigarette smoking and passive smoking is driving the demand for smoking cessation products in the region. For instance, according to the National Cancer Institute, approximately 7,330 individuals die each year due to lung cancer caused by passive smoking in the U.S.
   
• Additionally, the growing trend of quitting smoking and switching to other options like E-cigarettes has contributed to the country's rising market growth.
   

Europe: The smoking cessation and nicotine de-addiction market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• Rising awareness regarding quitting and nicotine de-addiction and initiatives taken by government are driving the adoption of NRT products such as gums and patches among teenagers, facilitating market growth in this region.
   
• Additionally, initiatives by government and regulatory organizations, such as the National Health Service (NHS), are promoting smoking cessation in the country. For instance, the Tobacco Control Plan by the UK government is working towards its goal to achieve a smoke-free England by 2030 (smoking rates below 5%).
   

Asia Pacific: Japan smoking cessation and nicotine de-addiction market is anticipated to witness lucrative growth between 2025 – 2034.
 

• The Japanese government has significantly increased taxes on tobacco products on multiple occasions, causing smoking to be very expensive in the region and thereby promoting smoking cessation. This has led to an increase in demand for NRT products.
   
• Additionally, the social acceptance of smoking among the younger generations and particularly in professional settings in Japan is increasing. For instance, as per the Statista, in December 2023, an estimated share of about 5% of the younger adults in Japan aged 15-19 had smoked in their lifetime. Growing concerns to curb smoking at a young age is further driving the adoption of NRT products in Japan.
   

Middle East and Africa: The smoking cessation and nicotine de-addiction market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• The implementation of free smoking cessation programs (such as Smoking Cessation Help Service) in clinics that provide NRTs and counselling across the country are driving the market growth.
   
• Additionally, increasing public awareness regarding the consequences of smoking and the various related diseases is encouraging smoking cessation among the public, facilitating market growth in the region.
   

Smoking Cessation and Nicotine De-addiction Market Share

The market is competitive, featuring both major global companies and numerous smaller firms. The top 5 players in this market include Cipla, GlaxoSmithKline, NJOY, Perrigo Company, and Pfizer. These players collectively account for approximately 40% market share. These players are investing in the development of advanced solutions to promote smoking cessation.
 

Moreover, strategic partnerships with research institutions and healthcare providers are critical for integrating modern technologies and expanding distribution, which will enable the companies to address the surge in demand for cost-effective solutions. The market experiences a regulatory support and streamlines approval processes which further motivates to innovate and facilitates market entry. Additionally, emerging players such as Rusan Pharma and Zydus Group are focussing on development of new diagnostic technologies, which aim to promote early diagnosis. These innovations continue to promote market progression.
 

Smoking Cessation and Nicotine De-addiction Market Companies

Some of the eminent market participants operating in the smoking cessation and nicotine de-addiction industry include:

• Alkalon
• British American Tobacco
• Cipla
• Dr. Reddy’s Laboratories
• GlaxoSmithKline
• Imperial Brands
• Johnson & Johnson
• Lupin
• NJOY
• Novartis
• Perrigo Company
• Pfizer
• Philip Morris International
• Rusan Pharma
• Zydus Group
   
• GlaxoSmithKline is a prominent player in the market, capturing a significant share of the market through its Bupropion (Zyban) product, a well-position NRT indicated for smoking cessation. Additionally, the company’s extensive global reach and advanced research and development capabilities is helping the company to grow its market share.
   
• Johnson and Johnson, through its Nicorette brand, captures a significant share of the OTC NRT market. The company’s extensive distribution network combined with its respiratory health expertise is helping in building trust among the consumers.
   
• Pfizer is a dominant player in the market. Its Chantix (varenicline) brand is one of the most popular medications for smoking cessation and boasts a widespread global adoption.
   

Smoking Cessation and Nicotine De-addiction Industry News:

• In June 2024, Dr. Reddy’s Laboratories announced the acquisition of the Nicotine Replacement Therapy portfolio of Haleon. The portfolio consists of popular brands such as Nicotinell, Nicabate, Thrive, and Habitrol having a widespread footprint across global markets outside the U.S. This acquisition is expected to significantly expand Dr. Reddy’s Laboratories’ reach in the global nicotine replacement therapy market.
   
• In December 2023, Lupin announced that the U.S FDA granted approval for its Varenicline tablets, a generic drug equivalent to Chantix, indicated for smoking cessation. The approval is expected to increase the accessibility of a variety of NRT and smoking cessation products, expanding the company’s reach in the market.
   

The smoking cessation and nicotine de-addiction market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Nicotine replacement therapy
  • Nicotine gum
  • Nicotine patches
  • Nicotine lozenges
  • Nicotine nasal sprays
  • Nicotine inhalers
• Drug therapy
  • Varenicline (Chantix)
  • Bupropion (Zyban)
• E-cigarettes and vapes

Market, By Route of Administration

• Oral
• Transdermal
• Nasal
• Inhalation
• Sublingual

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Spain
• Italy
• Netherlands

• Asia Pacific

• China
• Japan
• India
• Australia
• South Korea

• Latin America

• Brazil
• Mexico
• Argentina

• Middle East and Africa

• South Africa
• Saudi Arabia
• UAE